Developmental Therapeutics Program

发育治疗计划是从更基本的细胞周期和信号传递计划演变而来的， 在海伦·迪勒家庭综合癌症中心的历次更新周期中，谁被评为“杰出” 助学金。细胞周期和信号程序的研究主题与识别有关 以及治疗靶点的确认。其中许多靶点随后进入了临床前试验。 或准备在早期临床试验中进行探索。新的Eariy阶段临床试验单位已经创建 通过创新的设计和分析，有效地翻译这些主题的理想机会 研究方案。该计划由涉及13个不同部门的32名成员组成，并带来了 基础癌症生物学家和内科科学家的共同目标是发现和测试 癌症的新化合物和治疗策略该计划的主题是： 1)靶向信号转导通路(RTK、RAS、RAF/MAPK、P13‘K和WNT) 2)针对DNA复制和基因组完整性(细胞周期、端粒酶、HDAC) 3)血管生成 4)细胞凋亡 5)敏感性和抗性的遗传决定因素 计划成员的广泛专业知识将相互丰富和补充 个人研究人员，总体计划目标是加速药物发现的过渡 为癌症患者批准更有效和毒性更低的药物。 该计划的研究范围从药物发现、细胞信号、分子病理学和生物成像到 药物基因组学，以及临床和人口科学，最近在《自然》杂志上发表了影响很大的文章， 自然医学，自然遗传学，新英格兰医学杂志，临床肿瘤学杂志 生物化学，JAMA，美国国家科学院院刊，以及 柳叶刀。该方案在方案内和方案间所占的比例相当大，而且还在不断增加 出版物，反映了工作的主题广度和新出现的战略一体化努力 它的成员。该方案在上一个预算年度共获得了7,271,609美元的同行审查支助。这个 方案有12%的方案内出版物和13%的方案间出版物。

The Developmental Therapeutics Program evolved from the more basic Cell Cycling and Signaling Program, which scored "Outstanding" in prior renewal cycles ofthis Helen Diller Family Comprehensive Cancer Center support grant. The research themes ofthe Cell Cycling and Signaling Program were related to identification and validation of therapeutic targets. Many of these targets have subsequently moved into preclinical testing or are ready to be explored in early-stage clinical trials. The new Eariy Phase Clinical Trials Unit has created an ideal opportunity to translate these themes effectively, through the design and analysis of innovative research protocols. The Program comprises 32 members involving 13 different departments and brings together basic cancer biologists and physician scientists with the common goal of discovering and testing novel compounds and treatment strategies for cancer The Program themes are: 1) Targeting signal transduction pathways (RTKs, RAS, RAF/MAPK, Pl 3' kinase, and wnt) 2) Targeting DNA replication and genome integrity (cell cycle, telomerase, HDAC) 3) Angiogenesis 4) Apoptosis 5) Genetic determinants of sensitivity and resistance The wide range of expertise ofthe Program members will mutually enrich and complement the discoveries of individual investigators with the overall Program goal being to accelerate the transition from drug discovery to the approval of more effective and less toxic drugs for patients with cancer. Research in the Program spans from drug discovery, cell signaling, molecular pathology and bioimaging to pharmacogenomics, as well as clinical and population science with recent high impact publications in Nature, Nature Medicine, Nature Genetics, New England Journal of Medicine, Journal of Clinical Oncology, Journal of Biological Chemistry, JAMA, Proceedings of the National Academy of Science of the United States, and The Lancet. The Program has a sizable and increasing percentage of intra- and inter-programmatic publications, which reflect the thematic breadth of the work and the emerging efforts of strategic integration of its members. The Program had $7,271,609 total peer-reviewed support for the last budget year. The Program has 12% intra-programmatic and 13% inter-programmatic publications.